More articles from Volume 28, Issue 2, 2012
Reactive lymphadenopathy in daily practice
Diffuse large B cell lymphoma: variants, subgroups and subtypes/entities
Problematic 'low grade' lesions in lymphoproliferative pathology
Problematic 'high grade' lesions in lymphoproliferative pathology
Classical Hodgkin lymphoma: Differential diagnosis and tumour microenvironment
Article views
Prophylaxis and early detection of HPV-related neoplasia
Hans Ikenberg
Published: 01.12.2011.
Biochemistry
Volume 28, Issue 2 (2012)
pp. 577-585;
Abstract
References
1.
Bansal M, Austin . High-risk HPV dNa detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older. Gynecol Oncol. 2009;(2):257–61.
2.
Bohmer G, Van Den Brule. No confirmed case of human papillomavirus dNa-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. am j Obstet Gynecol. 2003;(1):118–20.
3.
Bory J, Cucherousset. recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int j Cancer. 2002;(5):519–25.
4.
Burger E, Kornor H. HPV mrNa tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol. 2011;(3):430–8.
5.
Carozzi F, Del Mistro. reproducibility of HPV dNa Testing by Hybrid Capture 2 in a screening setting. am j Clin Pathol. 2005;(5):716–21.
6.
Castle P, Cox . an analysis of high-risk human papillomavirus dNa-negative cervical precancers in the asCUs-LsIL Triage study (aLTs). Obstet Gynecol. 2008;(4):847–56.
7.
Castle P, Dockter. a cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger rNa assay for detection of cervical precancer and cancer. Clin Cancer res. 2007;(9):2599–605.
8.
Castle P, Fetterman B. Five-year experience of human papillomavirus dNa and Papanicolaou test cotesting. Obstet Gynecol. 2009;(3):595–600.
9.
Castle P, Gutierrez E. Evaluation of a new dNa test for detection of carcinogenic human papillomavirus. Clin Microbiol. 2011;(8):3029–32.
10.
Castle P, Rodriguez . short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMj. 2009;2569.
11.
Castle P. Human papillomavirus genotype specificity of hybrid capture 2. j Clin Microbiol. 2008;(8):2595–604.
12.
Castle P, Stoler M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the aTHENa study. Lancet Oncol. 2011;(9):880–90.
13.
Castle P, Wheeler C. Interlaboratory reliability of Hybrid Capture 2. am j Clin Pathol. 2004;(2):238–45.
14.
Cuzick J, L. Performance of the abbott realTime high-risk HPV test in women with abnormal cervical cytology smears. j Med Virol. 2010;(7):1186–91.
15.
Kreimer G. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl j Med. 2007;(19):1944–56.
16.
Einstein M, Martens M. Clinical validation of the Cervista HPV Hr and 16/18 genotyping tests for use in women with asC-Us cytology. Gynecol Oncol. 2010;(2):116–22.
17.
Frisch M, Glimelius B. sexually transmitted infection as a cause of anal cancer. N Engl j Med. 1997;(19):1350–8.
18.
Gravitt P, Peyton C. Improved amplification of genital human papillomaviruses. Clin Microbiol. 2000;(1):357–61.
19.
Guyot, Karim. Evaluation of adjunctive HPV testing by Hybrid Capture II in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy. BMC Infect dis. 2003;23.
20.
Heideman D, Hesselink . Clinical validation of the cobas(r)4800 HPV Test for cervical screening purposes. Clin Microbiol. 2011;
21.
Hesselink A, Bulkmans N. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCr method in a population-based cervical screening program. Clin Microbiol. 2006;(10):3680–5.
22.
Hesselink A, Heideman. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCr-enzyme immunoassay in population-based cervical screening. Clin Microbiol. 2010;(3):797–801.
23.
Hesselink A, Van Den Brule. Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer. 2004;(1):11–8.
24.
Jacobs M, P. a general primer GP5+/GP6(+)-mediated PCr-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. Clin Microbiol. 1997;(3):791–5.
25.
A, Magnusson P. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet. 2000;(9222):2189–93.
26.
Karlsen F, Kalantari M. Use of multiple PCr primer sets for optimal detection of human papillomavirus. Clin Microbiol. 1996;(9):2095–100.
27.
Katki H, Kinney W. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;(7):663–72.
28.
Khan M, Castle P. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. Natl Cancer Inst. 2005;(14):1072–9.
29.
Kinney W, Stoler M. special commentary: patient safety and the next generation of HPV dNa tests. am j Clin Pathol. 2010;(2):193–9.
30.
Kleter B, Van Doorn L. development and clinical evaluation of a highly sensitive PCr-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. Clin Microbiol. 1999;(8):2508–17.
31.
Lorincz A, Castle P. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet. 2002;(9328):228–9.
32.
Lorincz A, Smith J. sexually transmissible viral pathogens: Human papillomaviruses and herpes simplex viruses. Nucleic acid testing for human disease. Lorincz and j s smith. 2006;244–73.
33.
Mccrory D M, Bastian L. Evaluation of cervical cytology. 1999;
34.
Meijer C, Berkhof. Guidelines for human papillomavirus dNa test requirements for primary cervical cancer screening in women 30 years and older. Int j Cancer. 2009;(3):516–20.
35.
Mittendorf T, Nocon M. assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical. GMs Health Technol assess. 2007;8.
36.
Molden T, Kraus I. Comparison of human papillomavirus messenger rNa and dNa detection: a crosssectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev. 2005;(2):367–72.
37.
Qiao Y, . a new HPV-dNa test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;(10):929–36.
38.
Qu W, Jiang G. PCr detection of human papillomavirus: comparison between MY09/MY11 and GP5+/ GP6+ primer systems. Clin Microbiol. 1997;(6):1304–10.
39.
Quigley N, Potter N. rate of detection of high-risk HPV with two assays in women >/= 30 years of age. Clin Virol. 2011;(1):23–7.
40.
Quint W, Pagliusi S. results of the first World Health Organization international collaborative study of detection of human papillomavirus dNa. Clin Microbiol. 2006;(2):571–9.
41.
Rebolj M, Bonde. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. Ca Cancer j Clin. 2011;(2):342–62.
42.
Schiffman M, Khan M. a study of the impact of adding HPV types to cervical cancer screening and triage tests. Natl Cancer Inst. 2005;(2):147–50.
43.
Schiffman M, Wentzensen N. Human papillomavirus testing in the prevention of cervical cancer. Natl Cancer Inst. 2011;(5):368–83.
44.
Schmitt M, Bravo I. Bead-based multiplex genotyping of human papillomaviruses. Clin Microbiol. 2006;(2):504–12.
45.
Schmitt M, V. Dalstein. diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer res. 2010;(1):249–56.
46.
Kongres udruženja patologa i citologa srbije sa međunarodnim učešćem, Beograd 14-16 juna, 2012 14 th Congress of serbian association of Pathologists and Cytologists with international participation.
47.
Van Den Brule P. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. Pathol. 2003;(1):1–6.
48.
Stoler M, Wright T. High-risk human papillomavirus testing in women with asC-Us cytology: results from the aTHENa HPV study. am j Clin Pathol. 2011;(3):468–75.
49.
L. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008;(11):3033–42.
50.
Van Duin M, P. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int j Cancer. 2002;(4):590–5.
51.
Wang S, M. seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa rica. Br j Cancer. 2003;(7):1248–54.
52.
Wheeler C, Hunt W. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. Infect dis. 2006;(9):1291–9.
53.
Wright T, Cox . 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. jaMa. 2002;(16):2120–9.
54.
Wright T, Massad L. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. am j Obstet Gynecol. 2007;(4):346–55.
55.
Youens K, Hosler G. Clinical experience with the Cervista HPV Hr assay: correlation of cytology and HPV status from 56,501 specimens. Mol diagn. 2011;(2):160–6.
56.
Zielinski G, Bais . HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol surv. 2004;(7):543–53.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
